Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 7:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Topical Administration Clear all
Completed Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations

NCT05050149
View directory record Official record
Conditions
Microcystic Lymphatic Malformation
Interventions
PTX-022
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Little Rock, Arkansas • Palo Alto, California • Fridley, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 15, 2026, 7:59 AM EDT
Terminated Phase 2 Interventional Results available

1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX

NCT01692626
View directory record Official record
Conditions
Rash
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison Study of Topical Acne Regimens

NCT00913185
View directory record Official record
Conditions
Acne
Interventions
Acne Free, Proactiv
Drug
Lead sponsor
MedDerm Associates
Industry
Eligibility
13 Years to 45 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

NCT05388058
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy, Malignant Solid Neoplasm
Interventions
Cannabidiol, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
9
States / cities
Albert Lea, Minnesota • Grand Rapids, Minnesota • Hibbing, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 15, 2026, 7:59 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Treatment of Ocular Demodex Infestation With Topical Ivermectin Cream 1%

NCT05213585
View directory record Official record
Conditions
The Focus of the Study is to Assess the Effectiveness of Topical Ivermectin on Eliminating Eyelash Sleeves
Interventions
Ivermectin cream
Drug
Lead sponsor
Helm Vision Group
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Clarita, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens

NCT00495313
View directory record Official record
Conditions
Rosacea
Interventions
doxycycline
Drug
Lead sponsor
CollaGenex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
7
States / cities
Omaha, Nebraska • Las Vegas, Nevada • Arlington, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2008 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 4 Interventional

Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis

NCT01202149
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
Device
Lead sponsor
Frankel, Amylynne, M.D.
Other
Eligibility
2 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)

NCT01769352
View directory record Official record
Conditions
Post-surgical Cystoid Macular Edema (PSCME)
Interventions
PredA + Kelac
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 15, 2026, 7:59 AM EDT
Not listed Phase 2 Interventional

Topical Bimatoprost in the Treatment of Migraine

NCT03419715
View directory record Official record
Conditions
Migraine Disorders, Headache Disorders
Interventions
Bimatoprost Topical Solution, Control
Drug
Lead sponsor
Manistee Partners
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Cincinnati, Ohio • Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

NCT04135560
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
PF-07038124 and Vehicle, PF-07038124 or vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 15, 2026, 7:59 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)

NCT07426120
View directory record Official record
Conditions
Psoriasis Vulgaris, Topical Administration, Phase III
Interventions
Total coumarin (TC) cream, Vehicle cream
Drug
Lead sponsor
Psoriasis Research Institute of Guangzhou
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 2 Interventional

Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon

NCT00480753
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2007 · Synced Sep 15, 2026, 7:59 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females

NCT00856596
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot, Foot Fungus, Ringworm
Interventions
Sertaconazole nitrate cream 2%
Drug
Lead sponsor
Jamaica Hospital Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2009 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Not applicable Interventional

"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"

NCT01082523
View directory record Official record
Conditions
Acne, Patient Compliance
Interventions
Text message reminders
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 1Phase 2 Interventional

Treatment of Psoriasis With Parathyroid Hormone

NCT00007306
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Parathyroid hormone ointment
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 3, 2007 · Synced Sep 15, 2026, 7:59 AM EDT
Not listed Phase 3 Interventional

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

NCT00577304
View directory record Official record
Conditions
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
Interventions
Nitroglycerin, Topical AmphiMatrix
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
15 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2010 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

NCT04053387
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years to 75 Years
Enrollment
763 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
85
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 15, 2026, 7:59 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

NCT06594393
View directory record Official record
Conditions
Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
Interventions
TCP-25 gel, Vehicle (placebo)
Drug
Lead sponsor
Xinnate AB
Industry
Eligibility
4 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 1 Interventional

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

NCT03122353
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene and betamethasone suspension, Taclonex, Placebo
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
34
States / cities
Hot Springs, Arkansas • Fremont, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 3 Interventional

Phase III Study Evaluating Topical Benzocaine for Treatment of Acute Otitis Media in Children

NCT03116737
View directory record Official record
Conditions
Pain, Acute Otitis Media
Interventions
Benzocaine Otic Solution, Placebo
Drug
Lead sponsor
Lachlan Pharma Holdings
Industry
Eligibility
5 Years to 12 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Gresham, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 15, 2026, 7:59 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)

NCT00346502
View directory record Official record
Conditions
Dysplastic Nevus Syndrome
Interventions
20% betulinic acid ointment, BA
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.

NCT01177566
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
pimecrolimus, topical medical device
Drug · Device
Lead sponsor
Emer, Jason, M.D.
Individual
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2010 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01397695
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Bevacizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 15, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients

NCT00471445
View directory record Official record
Conditions
Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ketamine/amitriptyline NP-H cream, placebo
Drug · Other
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
17
States / cities
Honolulu, Hawaii • Chicago, Illinois • Decatur, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2015 · Synced Sep 15, 2026, 7:59 AM EDT